-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio Partners With Rafa to Commercialize ANKTIVA in Israel

PUBT·11/09/2026 12:03:58
Listen to the news
ImmunityBio Partners With Rafa to Commercialize ANKTIVA in Israel
  • ImmunityBio partnered with Rafa Laboratories as exclusive commercialization partner for ANKTIVA in Israel under a distribution agreement.
  • Israel authorized ANKTIVA with BCG for adults with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.
  • Approval came four months after submission under accelerated review; the registration license is expected within weeks.
  • ANKTIVA is now authorized in 35 countries.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611090700BIZWIRE_USPR_____20261109_BW516206) on November 09, 2026, and is solely responsible for the information contained therein.